The study can assure clinicians that Sandoz's Zarxio works just as well in febrile neutropenia as originator Amgen's Neupogen, author says in interview.
On Friday, the Food and Drug Administration approved the first biosimilar, marking an initial big step foward in changing the climate of the drug market in the United States. Time to save some money. Zarxio, produced by Sandoz, Inc. – a division of Novartis, is a drug that is designed to help the body produce […]
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.